Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

HUMA - Humacyte, Inc. Последние новости | Finranks

Home

/

HUMA

H

Humacyte, Inc. (HUMA)

NMS – Цена в реальном времени. Валюта: USD

0.64

-0.07 (-9.83%)

Рынок открыт: Aug 12, 2026, 11:40 AM EDT

0.70

-0.01 (-1.41%)

Предыдущая сессия: Aug 11, 2026, 7:46 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.24 per share a year ago.

Humacyte Q2 Earnings Call Highlights

Humacyte Q2 Earnings Call Highlights

Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study.

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engin.

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and six months ended June 30, 2026, on Wednesday, August 12, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts

Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from its prior day's close.

Видео

No Data

There is no data to display

Пресс-релизы

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engin.